Jove
Visualize
Contact Us

Related Concept Videos

Energy to Drive Translocation01:37

Energy to Drive Translocation

2.9K
Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
2.9K
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.6K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

363
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
363
Drive-Reduction Theory: Push Theory of Motivation01:27

Drive-Reduction Theory: Push Theory of Motivation

1.3K
Clark Hull's drive-reduction theory, introduced in the 1940s and 1950s and often termed the "push theory" of motivation, provides a framework for understanding how biological and learned drives influence behavior. Hull suggested that motivation originates from the need to alleviate physiological tension caused by unmet biological necessities. The theory proposes that when a basic need, such as hunger or sleep, goes unfulfilled, it creates an internal imbalance. This imbalance, or...
1.3K
In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

296
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
296

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and characterization of novel chikungunya virus polymerase inhibitors.

Journal of virology·2026
Same author

Discrete interneuron subsets participate in GluN1/GluN3A excitatory glycine receptor (eGlyR)-mediated regulation of hippocampal network activity throughout development and evolution.

Research square·2025
Same author

Identification and Characterization of Novel Chikungunya Virus Polymerase Inhibitors.

bioRxiv : the preprint server for biology·2025
Same author

Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.

Clinical and translational science·2025
Same author

Accelerating Oral Wound Healing Using Bilayer Biomaterial Delivery of FTY720 Immunotherapy.

Advanced healthcare materials·2024
Same author

Making new drugs the hard way.

Advances in pharmacology (San Diego, Calif.)·2024
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 10, 2026

Driving Under the Influence: How Music Listening Affects Driving Behaviors
07:25

Driving Under the Influence: How Music Listening Affects Driving Behaviors

Published on: March 27, 2019

13.1K

Academic Drug Development: The DRIVE Model.

Dennis Liotta1, George Painter2

  • 1Department of Chemistry and the Emory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States.

ACS Medicinal Chemistry Letters
|May 26, 2018
PubMed
Summary
This summary is machine-generated.

Academic drug development faces challenges in the "Valley of Death." The DRIVE model offers a robust framework for university-based drug development, particularly for rare and neglected diseases.

More Related Videos

Micro-drive Array for Chronic in vivo Recording: Drive Fabrication
14:03

Micro-drive Array for Chronic in vivo Recording: Drive Fabrication

Published on: April 20, 2009

25.9K
Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

5.1K

Related Experiment Videos

Last Updated: Feb 10, 2026

Driving Under the Influence: How Music Listening Affects Driving Behaviors
07:25

Driving Under the Influence: How Music Listening Affects Driving Behaviors

Published on: March 27, 2019

13.1K
Micro-drive Array for Chronic in vivo Recording: Drive Fabrication
14:03

Micro-drive Array for Chronic in vivo Recording: Drive Fabrication

Published on: April 20, 2009

25.9K
Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

5.1K

Area of Science:

  • Biomedical Research
  • Drug Development
  • Translational Science

Background:

  • Limited academic infrastructure exists for progressing drug discovery into clinical trials.
  • Academic drug development often struggles with insufficient funding, expertise, and infrastructure (the "Valley of Death").
  • Existing academic centers primarily focus on discovery, with fewer dedicated to comprehensive development.

Purpose of the Study:

  • To introduce and validate the DRIVE (Drug Innovation Ventures at Emory) model.
  • To demonstrate a framework for overcoming barriers in academic drug development.
  • To showcase the model's efficacy in advancing drugs for rare and neglected diseases.

Main Methods:

  • Establishment of a dedicated academic drug development center (DRIVE).
  • Integration of core competencies required for preclinical and clinical progression.
  • Focus on addressing the unique challenges of rare and neglected disease therapeutics.

Main Results:

  • The DRIVE model provides a viable framework for academic drug development.
  • Proof of concept achieved for the DRIVE model's operational effectiveness.
  • Successful advancement of drug candidates, particularly those for rare and neglected diseases.

Conclusions:

  • The DRIVE model effectively bridges the gap between drug discovery and clinical development in academia.
  • University-based drug development centers are crucial for tackling unmet medical needs, especially in rare diseases.
  • The DRIVE framework offers a scalable and sustainable solution for academic drug innovation.